Work

Abstract P3-07-08: Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in HR+/HER2- metastatic breast cancer (MBC)

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs22-p3-07-08

Authors: Sara Tolaney, Peter Schmid, Aditya Bardia, Frederik Marmé, Delphine Loirat, Priyanka Sharma, Hao Wang, Olivia Fu, Wendy Verret, Hope Rugo

Institutions: Dana-Farber Cancer Institute, Barts Cancer Institute, Massachusetts General Hospital, Heidelberg University, Medizinische Fakultät Mannheim, Institut Curie, University of Kansas Medical Center, Gilead Sciences (United States), University of California, San Francisco

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4322769412

Cites:

Cited by: 4

Related to: 10